argenx SE (NASDAQ:ARGX) Short Interest Update

argenx SE (NASDAQ:ARGX) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 1,200,000 shares, a decrease of 10.4% from the March 15th total of 1,340,000 shares. Based on an average trading volume of 332,500 shares, the short-interest ratio is currently 3.6 days.

argenx Trading Down 0.5 %

ARGX stock traded down $1.96 during midday trading on Tuesday, hitting $374.30. The stock had a trading volume of 146,294 shares, compared to its average volume of 319,214. The firm has a market cap of $22.20 billion, a P/E ratio of -72.50 and a beta of 0.65. argenx has a 1-year low of $327.73 and a 1-year high of $550.76. The business has a fifty day moving average price of $389.95 and a two-hundred day moving average price of $423.50.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). The company had revenue of $417.84 million during the quarter, compared to analysts’ expectations of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the prior year, the firm earned ($0.70) EPS. On average, equities analysts anticipate that argenx will post -2 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on ARGX. HC Wainwright reaffirmed a “buy” rating and issued a $451.00 price target on shares of argenx in a report on Wednesday, March 27th. Truist Financial upped their price objective on argenx from $370.00 to $440.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. William Blair lowered argenx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Wolfe Research assumed coverage on argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Finally, Wells Fargo & Company increased their price target on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 20th. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and an average target price of $530.74.

Hedge Funds Weigh In On argenx

A number of large investors have recently added to or reduced their stakes in the company. Nkcfo LLC boosted its position in argenx by 22.1% in the third quarter. Nkcfo LLC now owns 116 shares of the company’s stock valued at $57,000 after buying an additional 21 shares during the last quarter. Genus Capital Management Inc. raised its stake in argenx by 1.6% in the 3rd quarter. Genus Capital Management Inc. now owns 1,605 shares of the company’s stock valued at $789,000 after purchasing an additional 25 shares during the last quarter. Creative Planning increased its stake in shares of argenx by 3.0% in the 4th quarter. Creative Planning now owns 1,006 shares of the company’s stock worth $381,000 after acquiring an additional 29 shares during the last quarter. Snowden Capital Advisors LLC increased its stake in shares of argenx by 1.9% in the 1st quarter. Snowden Capital Advisors LLC now owns 1,920 shares of the company’s stock worth $715,000 after acquiring an additional 35 shares during the last quarter. Finally, Wahed Invest LLC increased its stake in shares of argenx by 9.6% in the 4th quarter. Wahed Invest LLC now owns 457 shares of the company’s stock worth $174,000 after acquiring an additional 40 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.